# Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand

> **NCT05052502** · NA · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 14977 (actual)

## Conditions studied

- Plasmodium Falciparum Malaria
- Plasmodium Vivax Malaria

## Interventions

- **OTHER:** Case Management and Follow-up
- **OTHER:** Reactive focal mass drug administration (rfMDA)

## Key facts

- **NCT ID:** NCT05052502
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-01
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 14977 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05052502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05052502, "Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05052502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*